PMID- 34976152
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220104
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Jan
TI  - Feibi decoction-medicated serum inhibits lipopolysaccharide-induced inflammation 
      in RAW264.7 cells and BMDMs.
PG  - 110
LID - 10.3892/etm.2021.11033 [doi]
LID - 110
AB  - Feibi decoction (FBD) is a traditional Chinese herbal medicine and has been 
      clinically used in the treatment of pulmonary fibrosis (PF), which is 
      characterized by diffuse interstitial inflammation and exaggerated collagen 
      accumulation. However, the potential mechanisms remain to be elucidated. The 
      present study aimed to investigate the effect of FBD-medicated serum (FBDS) on 
      lipopolysaccharide (LPS)-induced inflammation in macrophages. In RAW264.7 
      macrophages and bone marrow-derived macrophages (BMDMs), FBDS treatment 
      significantly inhibited the production of pro-inflammatory cytokines induced by 
      LPS. In addition, it was indicated that FBDS treatment suppressed the activation 
      of NF-kappaB and Smad2/Smad3 following LPS treatment. Furthermore, FBDS treatment 
      decreased the expression of transforming growth factor-beta1 and chitinase-3-like 
      protein 1. In conclusion, the results demonstrated that treatment with FBDS 
      inhibited LPS-induced inflammation in RAW264.7 and BMDM cells. These data may 
      improve understanding of the effect of FBD on anti-inflammation and help 
      determine the mechanisms underlying the alleviation of PF via FBD.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Wei, Wan
AU  - Wei W
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. 
      China.
AD  - Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 
      100078, P.R. China.
FAU - Li, Guodong
AU  - Li G
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. 
      China.
FAU - Liu, Zhaoheng
AU  - Liu Z
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. 
      China.
FAU - Yang, Haojie
AU  - Yang H
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. 
      China.
FAU - Liu, Shuo
AU  - Liu S
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. 
      China.
FAU - Zou, Xinxin
AU  - Zou X
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. 
      China.
FAU - Jiao, Yang
AU  - Jiao Y
AD  - Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 
      100078, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20211202
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC8674952
OTO - NOTNLM
OT  - feibi decoction
OT  - inflammation
OT  - pulmonary fibrosis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/01/04 06:00
MHDA- 2022/01/04 06:01
PMCR- 2021/12/02
CRDT- 2022/01/03 05:40
PHST- 2018/08/16 00:00 [received]
PHST- 2021/07/06 00:00 [accepted]
PHST- 2022/01/03 05:40 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/01/04 06:01 [medline]
PHST- 2021/12/02 00:00 [pmc-release]
AID - ETM-0-0-11033 [pii]
AID - 10.3892/etm.2021.11033 [doi]
PST - ppublish
SO  - Exp Ther Med. 2022 Jan;23(1):110. doi: 10.3892/etm.2021.11033. Epub 2021 Dec 2.